Commentary

Off-Label Use of Medications


 

It is unsettled whether a physician is obligated to inform patients that a drug’s proposed use is considered off label. As a practical matter, it may be difficult to explain why its use is as yet unapproved by the FDA. Besides, the public is guarded over off-label prescriptions, approximately half believing that such uses should be prohibited. A patient may reasonably want to know whether a drug or device is being used in an approved or unapproved manner, in addition to knowing its benefits and risks. This has led some observers to call for a legal requirement of disclosure.

Dr. Tan is a former professor of medicine and adjunct professor of law at the University of Hawaii. This column, "Law and Medicine," regularly appears in Internal Medicine News, an Elsevier publication; it is meant to be educational and does not constitute medical, ethical or legal advice. It is adapted from the author’s book, "Medical Malpractice: Understanding the Law, Managing the Risk" (2006). For additional information, readers may contact the author at siang@hawaii.edu.

Pages

Recommended Reading

Prom Tanning in '90s Behind Current Spike in Melanoma
MDedge Hematology and Oncology
New Diarrheal Syndrome Tied to Cord-Blood Transplants
MDedge Hematology and Oncology
Crizotinib Approval Personalizes Lung Cancer Therapy
MDedge Hematology and Oncology
Community Oncology Podcast - Vandetanib in advanced hereditary medullary thyroid cancer
MDedge Hematology and Oncology
Quality care is a team effort
MDedge Hematology and Oncology
Personalized medicine: myth to reality
MDedge Hematology and Oncology
The wearable external cardiac defibrillator for cancer patients at risk for sudden cardiac death
MDedge Hematology and Oncology
CASE LETTER Mandibular fracture in a patient treated with long-term antiangiogenic therapy and previous bisphosphonate exposure
MDedge Hematology and Oncology
Medicare Shared Savings Program ignores oncology—but value-based reimbursement is on the way
MDedge Hematology and Oncology
Molecular tumor profile: another consideration for postmastectomy radiotherapy
MDedge Hematology and Oncology